BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morgan JR, Wang J, Barocas JA, Jaeger JL, Durham NN, Babakhanlou-Chase H, Bharel M, Walley AY, Linas BP. Opioid overdose and inpatient care for substance use disorder care in Massachusetts. J Subst Abuse Treat 2020;112:42-8. [PMID: 32199545 DOI: 10.1016/j.jsat.2020.01.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Morgan JR, Freibott CE, Jalali A, Jeng PJ, Walley AY, Chatterjee A, Green TC, Nolan ML, Linas BP, Marshall BD, Murphy SM. The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City. Drug and Alcohol Dependence Reports 2022;4:100083. [DOI: 10.1016/j.dadr.2022.100083] [Reference Citation Analysis]
2 Morgan JR, Murphy SM, Assoumou SA, Linas BP. Estimating Absenteeism Related to Nonalcohol Substance Use in a US National Cohort of Full-Time Employees. Journal of Occupational & Environmental Medicine 2022;Publish Ahead of Print. [DOI: 10.1097/jom.0000000000002612] [Reference Citation Analysis]
3 Morgan JR, LaRochelle MR. Commentary on Karnik et al.: Harmonization now-the need for consistent, validated measures to identify opioid use disorder in observational data. Addiction 2022. [PMID: 35762525 DOI: 10.1111/add.15977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ameral V, Hocking E, Leviyah X, Newberger NG, Timko C, Livingston N. Innovating for real-world care: A systematic review of interventions to improve post-detoxification outcomes for opioid use disorder. Drug and Alcohol Dependence 2022;233:109379. [DOI: 10.1016/j.drugalcdep.2022.109379] [Reference Citation Analysis]
5 Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction 2022. [PMID: 35315162 DOI: 10.1111/add.15879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Neighbors CJ, Hussain S, O'Grady M, Manseau M, Choi S, Hu X, Burke C, Lincourt P. Predictive validity of the New York State Level of Care for Alcohol and Drug Treatment Referral (LOCADTR) for continuous engagement in treatment among individuals recommended for outpatient care. J Subst Abuse Treat 2021;:108559. [PMID: 34272131 DOI: 10.1016/j.jsat.2021.108559] [Reference Citation Analysis]
7 Crystal S, Nowels M, Olfson M, Samples H, Williams AR, Treitler P. Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration. J Subst Abuse Treat 2021;:108546. [PMID: 34391586 DOI: 10.1016/j.jsat.2021.108546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Morgan JR, Barocas JA, Murphy SM, Epstein RL, Stein MD, Schackman BR, Walley AY, Linas BP. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. JAMA Netw Open 2020;3:e2029676. [PMID: 33320266 DOI: 10.1001/jamanetworkopen.2020.29676] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]